BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Phone+1-510-5213390
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees76
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
How were BioTime's earnings last quarter?
BioTime, Inc. (NYSEAMERICAN:BTX) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biotechnology company earned $0.78 million during the quarter, compared to analyst estimates of $1.04 million. View BioTime's Earnings History.
When is BioTime's next earnings date?
What price target have analysts set for BTX?
6 brokerages have issued twelve-month price targets for BioTime's stock. Their predictions range from $3.00 to $5.00. On average, they expect BioTime's stock price to reach $3.80 in the next year. This suggests a possible upside of 313.1% from the stock's current price. View Analyst Price Targets for BioTime.
What is the consensus analysts' recommendation for BioTime?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.
What are Wall Street analysts saying about BioTime stock?
Here are some recent quotes from research analysts about BioTime stock:
- 1. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (8/9/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities for OpRegen (approximately 57% valuation contribution) on only the U.S. opportunity and Renevia (43% valuation contribution) in the E.U. We note that our current projected values for both these assets are based on minimal market penetration in very large markets." (8/9/2019)
- 3. Maxim Group analysts commented, "BioTime announced that its affiliate, OncoCyte (OCX – NR, BTX has 36% stake), reported positive results from an R&D validation study of DetermaVu, a non- invasive, liquid biopsy test for the early diagnosis of lung cancer. On this news, BioTime shares on 1/29 were up ~50%, OncoCyte shares were up over 200%, and even Asterias (AST – NR) shares, a cell therapy company soon to be fully acquired by BioTime, were up ~45%." (1/30/2019)
Has BioTime been receiving favorable news coverage?
News coverage about BTX stock has been trending positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTime earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for BioTime.
Who are some of BioTime's key competitors?
Some companies that are related to BioTime include Neptune Wellness Solutions (NEPT), Oxford BioMedica (OXB), Starpharma (SPL), BELLUS Health (BLU), Kodiak Sciences (KOD), Biotest (BIO), Theratechnologies (TH), Monash IVF Group (MVF), Emerald Health Therapeutics (EMH), Rafael (RFL), ProMetic Life Sciences (PLI), CEL-SCI (CVM), Paradigm Biopharmaceuticals (PAR), Emblem (EMC) and 22nd Century Group (XXII).
What other stocks do shareholders of BioTime own?
Who are BioTime's key executives?
BioTime's management team includes the folowing people:
- Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
- Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
- Mr. Brian M. Culley, CEO, Pres & Director (Age 48)
- Ms. Brandi L. Roberts, CFO & Sec. (Age 45)
- Ioana C. Hone, Director of Investor Relations
Who are BioTime's major shareholders?
BioTime's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.74%), Vanguard Group Inc. (3.55%), Defender Capital LLC. (2.75%), Northern Trust Corp (0.83%), Northeast Financial Consultants Inc (0.37%) and Bank of New York Mellon Corp (0.27%). Company insiders that own BioTime stock include Aditya P Mohanty, Biotime Inc, Brian M Culley, Broadwood Partners, LP, Chase C Leavitt, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.
Which institutional investors are selling BioTime stock?
BTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Defender Capital LLC., Jane Street Group LLC, Bank of New York Mellon Corp and Morgan Stanley. View Insider Buying and Selling for BioTime.
Which institutional investors are buying BioTime stock?
BTX stock was acquired by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Northeast Financial Consultants Inc, Vanguard Group Inc., Creative Planning, Zacks Investment Management, A.R.T. Advisors LLC, Acadian Asset Management LLC and Beirne Wealth Consulting Services LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Brian M Culley, Broadwood Partners, LP, Chase C Leavitt, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.
How do I buy shares of BioTime?
Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTime's stock price today?
One share of BTX stock can currently be purchased for approximately $0.9199.
How big of a company is BioTime?
What is BioTime's official website?
How can I contact BioTime?
BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.
MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
